ABSTRACT The effects of abrupt withdrawal or continuation of fl-blockade therapy during acute myocardial infarction were evaluated in 326 patients participating in the Multicenter Investigation of the Limitation of Infarct Size (MILIS). Thirty-nine patients previously receiving a f8-blocker and randomly selected for withdrawal of fl-blockers and placebo treatment during infarction (group 1) were compared with 272 patients previously untreated with fl-blockers who were also randomly assigned to placebo therapy (group 2). There were no significant differences between the two groups in MB creatine kinase isoenzyme (15.8 10.9 vs 18.2 + 14.4 g-eq/m2, respectively) estimates of infarct size, radionuclide-determined left ventricular ejection fractions within 18 hr of infarction (0.44 0.15 vs 0.47 0.16) or 10 days later (0.42 0.14 vs 0.47 0.16), creatine kinase-determined incidence of infarct extension (13% vs 6%), congestive heart failure (43% vs 37%), nonfatal ventricular fibrillation (5% vs 7%), or in-hospital mortality (13% vs 9%). Patients in group 1 had more recurrent ischemic chest pain (p = .002) within the first 24 hr after infarction, but not thereafter. However, this did not appear to be related to a rebound increase in systolic blood pressure, heart rate, or double product. In a separate analysis, 20 propranolol-eligible group 1 patients randomly selected for withdrawal of fl-blockade (group 3) were compared with 15 patients randomly selected for continuation of prior fiblockade therapy (group 4). This comparison yielded similar results. These data indicate that the ,f-blockade withdrawal phenomenon is not a major clinical problem in patients with acute myocardial infarction. f-Blockade therapy can be discontinued abruptly during acute myocardial infarction if clinically indicated.
receptors and/or an alteration in their affinity for /3-adrenergic agonists,'2 or rebound hypersensitivity to sympathetic stimulation.4 ' 11, 13 14 Considerable controversy surrounds the existence of a /3-blockade withdrawal phenomenon. 25, 11, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] Moreover, accurate clinical evaluation of the syndrome is confounded by an inability to distinguish between reemergence of symptoms after cessation of effective therapy and true rebound phenomena. It is reasonable, however, to postulate that rebound /3-adrenergic hypersensitivity is most likely to be unmasked during acute myocardial infarction, a condition characterized by marked elevation of both plasma25-27 and local myocardial catecholamine levels. 28, 29 In this situation too, urgent questions regarding the relative risks of abrupt withdrawal vs continuation of /3-blockers frequently arise. This report describes the hospital course and prospectively collected measurements of infarct size, left ventricular function, and cardiac arrhythmias in clinically comparable groups of patients with acute myocardial infarction with and without abrupt withdrawal of /3-blockade.
Methods
Study population. Three hundred twenty-six patients presenting with enzymatically confirmed acute myocardial infarction were studied. These 326 patients formed part of the larger cohort of individuals enrolled in the Multicenter Investigation of the Limitation of Infarct Size (MILIS) study,30' 31 a randomized blinded trial designed to assess the efficacy of propranolol or hyaluronidase vs placebo in limiting infarct size.
Each patient fulfilled previously defined inclusion and exclusion criteria30' 32 for entry into the study. The 1-BL tion to either hyaluronidase or placebo. Adverse clinical criteria dictating assignment to group B included (1) a heart rate less than 55 beats/min at the time of randomization or less than 40 beats/min before randomization, (2) a systolic arterial pressure less than 100 mm Hg at randomization, one that had fallen more than 50 mm Hg from previous levels, or one that even temporarily was less than 70 mm Hg, (3) moist rales over one-third or more of the lung fields, (4) the presence of atrioventricular block, (5) a history of asthma, (6) wheezes on physical examination, (7) pulmonary edema, or (8) administration of verapamil within the previous 6 hr. 30 The 326 patients in this study were divided into four groups (figure 1). For purposes of comparing the clinical courses of patients withdrawn from ,3-blockade during acute myocardial infarction and those never exposed to ,1-blockade, we evaluated patients in two groups. Group I consisted of 39 patients previously taking a ,8-blocker regularly for at least 21 days before randomization who were randomly selected for abrupt withdrawal of 18-blockade and administration of placebo. Group 2 consisted of 272 patients not previously on a 13-blocker who were randomly selected to receive placebo.
To compare the relative effects of l3-blockade withdrawal vs continuation during acute myocardial infarction, we also identified two other groups of patients. Because patients continued on 1-blockade (group 4) had to fulfill MILIS criteria for propranolol eligibility (defined above), we required that patients withdrawn from 1-blockade (group 3) also fulfill similar baseline clinical characteristics. Group 3 patients were selected as a subgroup of group 1 and comprised all 20 patients in this latter group who were eligible for propranolol but who were randomly assigned to abrupt withdrawal of13-blockade and administration of placebo. Group 4 comprised all 15 patients in the MILIS study previously taking a 13-blocker regularly for at least 21 days before admission who were eligible for and randomly assigned to therapy with propranolol. All group 4 patients completed intravenous induction of propranolol (0.1 mg/kg in three divided doses over 6 min), intravenous maintenance therapy (onequarter of the induction dose given intravenously over 30 sec), and oral maintenance therapy over a period of 9 days (individualized dosage according to the MILIS protocol).
Radionuclide ventriculography. Radionuclide ventriculograms deemed interpretable by the MILIS Core Laboratory for Radionuclide Ventriculography were obtained before randomization and within 18 hr of the onset of chest pain in 291 patients. , we required that all group 3 patients fulfill similar baseline characteristics. Therefore group 3 patients were selected from all those withdrawn from /3-blockade therapy (group 1) and comprised only those in this latter group who were propranolol-eligible (by MILIS criteria).
--
THERAPY AND PREVENTION-3-ADRENERGIC BLOCKADE
Two hundred seventy-three patients underwent repeat resting radionuclide ventriculography 10 days after myocardial infarction. Multigated equilibrium blood pool scintigrams were obtained by previously described techniques32 and were analyzed by blinded investigators. Left ventricular ejection fraction, end-diastolic volume index, and an average wall motion score were calculated by methods reported previously.32.
Enzymatic estimation of infarct size. Serial blood samples from each patient were assayed for the MB creatine kinase isoenzyme by the glass-bead adsorption technique.3 Samples were drawn from an indwelling heparin lock on admission, hourly thereafter for 4 hr, every 2 hr for the next 4 hr, and then every 4 hr until completion of a 72 hr interval. Additional samples were drawn every 8 hr for the next 48 hr and then every 12 hr for the next 9 days. MB creatine kinase values were used to construct time-activity curves, from which infarct size could be derived.34 Results Incidence of prior angina and infarction. Table 2 details the level of patient activity producing angina 3 weeks before admission with acute myocardial infarction. Patients in group 1 had a greater incidence of angina (p < .0005) and of previous transmural myocardial infarction (p < .0005) than those in group 2. This, and the greater incidence of hypertension (table 1) in group 1 patients, presumably accounted for their prior therapy with fl-blockers. There was no significant difference in the incidence of angina or of previous transmural infarction between groups 3 and 4.
Electrocardiographic classification of acute infarction.
There was no difference between groups 1 and 2 or groups 3 and 4 in the incidence of either transmural (Q wave) or nontransmural (non-Q wave) acute myocardial infarction (table 3) .
Enzymatic and pyrophosphate scintigraphic estimates of infarct size Group 1 vs group 2. The MB creatine kinase infarct size index (15.8 ± 10.9 g-eq/m2) in patients in group 1 was not significantly different from that in group 2 (18.2 ± 14.4 g-eq/m2). Similarly, myocardial infarct areas determined by planimetry of 9rmTc-pyrophos- ischemic chest pain during the first 24 hr after randomization (2.4 ± 2.4 vs 1.2 ± 2.0; p < .005) and a marginally greater number of episodes during the second 24 hr period (0.9 ± 1.6 vs 0.5 ± 1.0 p = .08) than did group 2 patients. During each of the ensuing 9 days, there was no statistically significant difference between the two groups in the frequency of anginal pain. No differences were detected between the two groups with respect to the incidence of orthopnea, rales extending over more than one-third of the lung fields, or the presence of a third heart sound or murmur of mitral regurgitation during any 24 hr period within the first 11 days after randomization. figure 3 . The minimum and maximum double products were higher in those in whom prior ,l-blockade therapy was stopped after randomization (group 3) than in those in whom f8-blockade therapy was continued after randomization (group 4) during most of the study period. This was due to the effects of continued f8-blockade in the latter group. There did not appear to be a transient rebound increase in double product in group 3 patients (figure 3). Group 3 patients had a greater frequency of chest pain than group 4 patients during the first 24 hr after randomization (2.8 ± 2.7 vs 0.8 ± 0.8; p < .005) but not during any of the ensuing 10 days. The two groups did not differ significantly in the incidence of orthopnea, rales extending over more than one-third of the lung fields, or the presence of an S3 or murmur of mitral regurgitation during any 24 hr period up to the eleventh day after randomization.
Hospital complications occurring in patients in groups 3 and 4 are listed in table 5. There was no significant difference in the occurrence of any in-hospital complication analyzed. However, patients withdrawn from /3-blocker therapy exhibited a trend toward a higher incidence of sinus tachycardia (p = .06), impulse conduction defects (p -.28), congestive heart failure (p = .13), and cardiogenic shock (p = .24). Two patients (10%) who were withdrawn from /-blocker therapy (group 3) and one patient (7%) who continued on propranolol (group 4) had enzyme-determined infarct extension.31 Two group 3 (10%) and two group 4 (13%) patients died while in the hospital.
Discussion
The /3-blockade withdrawal syndrome was first described in a series of case reports. 1 21 and diverse objective criteria4 S 8, 10, 11, [13] [14] [15] [16] 36 used to define a rebound phenomenon. Our study is the first detailed report of the effects of withdrawal of /3-blockade in large numbers of patients during acute myocardial infarction, a hyperadrenergic state25-29, 42 and the condition during which urgent decisions regarding abrupt withdrawal of /3-blockers are most frequently required.
The data presented here indicate that withdrawal of ,/-blockade in patients with acute myocardial infarction did not result in a greater initial infarct size, worse left ventricular function 10 days after infarction, or a higher in-hospital mortality than were seen in a comparable group of patients never exposed to /3-blockade.
Furthermore, abrupt withdrawal of /3-blockade did not result in either a greater incidence of creatine kinasedetermined infarct extension or in-hospital congestive heart failure or arrhythmias, including nonfatal ventricular fibrillation. Similar results were obtained in a * References 8, 10, 11, 13, 15, 16, 18-23, 36, 38, 39 Comparison of maximum and minimum heart rates, blood pressures, and double products (heart rate X systolic blood pressure) in each 24 hr period during the first 11 days after acute myocardial infarction in patients in groups 3 and 4. Asterisks directly above values indicate a significant difference in that value between patients in groups 3 and 4 on that day (*p < .05; **p < .0002).
comparison of patients previously taking fl-blockers and eligible for randomization to fl-blockers after infarction, who received either placebo (group 3) or propranolol (group 4). Also noteworthy is the fact that there was no evidence of a rebound increase in systolic blood pressure, heart rate, or double product, frequently used indexes of myocardial oxygen consumption,43 44 in the group 1 patients. Although the plot of daily maximum heart rate for group 3 patients ( figure  3 ) suggests a rebound increase in heart rate after withdrawal of fl-blockade, there was no apparent rise in maximum double product in the ensuing 4 days. Although the data presented here suggest that fiblockers may, when clinically indicated, be discontinued abruptly at the onset of acute myocardial infarction with an acceptable risk, it should be emphasized that they are derived from a post-hoc analysis of the MILIS study, the original design of which did not include a hypothesis regarding the question of a fl-blockade withdrawal syndrome.
In both sets of comparisons (groups 1 vs 2 and groups 3 vs 4), patients in whom f-blockade was abruptly withdrawn (group 1 and group 3) had a higher incidence of ischemic chest pain during the first 24 hr after infarction. However, this did not appear to be related to an exaggregated increase in heart rate, systolic blood pressure, or double product in group 1 patients. Group 3 patients displayed a higher maximum double product during day 1 but also during most of the ensuing 10 days, when there was no difference in the frequency of ischemic pain. We cannot exclude the possibility that the observed early increased incidence of recurrent ischemic chest pain may have been caused by "rebound" increases in left ventricular size or contractility, two additional determinants of myocardial oxygen consumption." However, others21 have failed to demonstrate echocardiographic evidence of increases in these determinants after withdrawal of propranolol and exercise provocation in normal subjects and patients with angina. The prolonged (24 hr'7 and possibly even as long as 72 hil5) cardiac and hemodynamic actions of propranolol, the predominant fiblocker used before infarction in our patients, also argues against a major withdrawal effect within the first 24 hr.
An alternative explanation for the increased frequency of recurrent chest pain within the first 24 hr after withdrawal of fl-blockers is based on a postulated temporal dissociation of the effects of these agents on myocardial oxygen supply and demand during the period of withdrawal. fl-Blockers not only decrease myocardial oxygen demand`6 47 through their negative inotropic, chronotropic, antihypertensive, and antilipolytic effects, but they may also decrease myocardial oxygen supply46 48 through their effect on diastolic blood pressure46 and enhancement of coronary vasoconstriction.48 An imbalance between these relative effects during the withdrawal period, with persistent limitation of coronary flow when myocardial oxygen demand is rising, might also contribute to the observed transiently increased frequency of angina. Indeed, the effects of propranolol appear to be temporally dissociated, 17 with a shorter duration of its negative inotropic than chronotropic effect. 15 17, 41 Patients in whom fl-blockers were discontinued (group 1) had a higher incidence of impulse conduction defects (p = .05) and cardiogenic shock (p = .05) than patients never exposed to such therapy (group 2). This was confirmed in a separate analysis of patients with similar baseline characteristics (group 3 vs group 4). These data suggest that the higher incidence of cardiogenic shock in group 5 and hypertension '10 11, 13 and in normal individuals '1' 16 have provided evidence for a rebound syndrome after withdrawal of /-blockade. Since withdrawal reactions were most prominent among patients with angina deriving the greatest antianginal benefit from the drug,4 these phenomena may simply be related to the removal of a therapeutic agent initially instituted for, and effectively suppressing, anginal episodes rather than to a "rebound effect."' '8 In confirmatory studies in patients with hypertension,'°0 11, 13 the possibility that altered baroreceptor responses or other pathophysiologic alterations unique to the hypertensive state may have contributed to the observed results must also be considered. Moreover, our study of patients with acute myocardial infarction using /3-blockers for at least 3 weeks previously is likely to be more relevant to the usual situation in which urgent decisions regarding abrupt withdrawal of /3-blockade are required.
Whereas most of the patients in this study were taking propranolol at the time of randomization, a few were taking other /3-blockers. Although it has been argued that a propranolol rebound hypersensitivity should not be extrapolated to other /-blockers,52 withdrawal symptoms have been described to occur with timolol,53 a noncardioselective agent, and with ateno1o154 and metoprolol,55 56 which are cardioselective. Furthermore, no difference in the severity of this phenomenon has been observed after withdrawal of atenolol, oxprenolol, or acebutolol'6 or in its time course after withdrawal of oxprenolol or metoprolol. 14 Therefore it is unlikely that the prior use of different /3-blockers altered the rebound phenomenon.
Patients taken off /3-blockers at the onset of myocardial infarction (groups 1 and 3) varied widely in their previous daily dosages of propranolol. Therefore individual patients, particularly those taking lower dosages, may not The data from this study suggest that ,8-blockers can be discontinued abruptly in the patient with acute infarction with an acceptable risk when clinically indicated.
